Laverock Therapeutics awarded £2.2M grants

MiNK Therapeutics, a biotechnology company, has been awarded two new grants totaling over £2.2M. These grants will support the development of its single-cell and AI-powered gene-control platform and facilitate the expansion of its therapeutic programs into non-oncology areas. The funding validates MiNK Therapeutics' differentiated technology and pipeline, building on previous non-dilutive funding from United Kingdom — UK Research and Innovation. The first grant project focuses on scaling the platform within a T-cell product context for solid tumor indications, leveraging AI-powered approaches. The second grant will enable the expansion of MiNK Therapeutics' macrophage-based programs into non-oncology indications, involving a consortium effort for rapid clinical translation. David Venables, CEO of MiNK Therapeutics, emphasized that this funding will unlock the full potential of their technology as they advance towards clinical trials.